Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Change in Accured Expenses (2019 - 2025)

Biodesix (BDSX) has disclosed Change in Accured Expenses for 7 consecutive years, with $974000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 42.5% year-over-year to $974000.0, compared with a TTM value of $1.9 million through Dec 2025, up 13.56%, and an annual FY2025 reading of $1.9 million, up 13.56% over the prior year.
  • Change in Accured Expenses was $974000.0 for Q4 2025 at Biodesix, up from $486000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.3 million in Q2 2023 and bottomed at -$5.7 million in Q1 2021.
  • Average Change in Accured Expenses over 5 years is -$209450.0, with a median of $338500.0 recorded in 2021.
  • The sharpest move saw Change in Accured Expenses plummeted 770.25% in 2021, then skyrocketed 2897.25% in 2023.
  • Year by year, Change in Accured Expenses stood at $1.8 million in 2021, then plummeted by 106.91% to -$127000.0 in 2022, then soared by 698.43% to $760000.0 in 2023, then soared by 122.89% to $1.7 million in 2024, then plummeted by 42.5% to $974000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for BDSX at $974000.0 in Q4 2025, $486000.0 in Q3 2025, and $2.3 million in Q2 2025.